LBIO 115
Alternative Names: LBIO-115Latest Information Update: 11 Oct 2023
Price :
$50 *
At a glance
- Originator Locanabio
- Class Gene therapies; RNA
- Mechanism of Action Dystrophin expression stimulants; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 06 Oct 2023 Locanabio announces intention to submit IND application to the US FDA for Duchenne muscular dystrophy in mid-2024
- 06 Oct 2023 Pharmacodynamics data from a preclinical trial in Duchenne muscular dystrophy released by Locanabio
- 16 May 2023 Pharmacodynamics data from a preclinical trials in Duchenne muscular dystrophy released by Locanabio